Parkinson Disease Individualize by careful titration.
Immediate-release:PO 0.25 mg 3 times daily initially. Based on response, dosage may be increased weekly by 0.25 mg/day up to 3 mg/day, then by 1.5 mg/day up to 9 mg/day, then by 3 mg/day to total dose of 24 mg/day.
Extended-release:PO Start with 2 mg once daily for 1 to 2 wk, followed by increases of 2 mg/day at 1-wk intervals as appropriate, depending on therapeutic response and tolerability (max, 24 mg/day). Patients may be switched directly from immediate-release. The initial dose of the ER formulation should most closely match the total daily dose of the immediate-release formulation. Following conversion, the dose may be adjusted depending on therapeutic response and tolerability.
Adults:PO 0.25 mg once daily 1 to 3 h before bedtime. After 2 days, dose may be increased to 0.5 mg once daily, then to 1 mg once daily at end of first wk; dose may then be increased in 0.5 mg/day increments weekly for 5 additional wk, and then by 1 mg/day after 6 wk (max, 4 mg once daily).